The ventral tegmental area (VTA) plays a critical role in motivation and reinforcement.
Introduction
The ventral tegmental area (VTA) contributes to the motivational actions of natural rewards and a variety of drugs including opioid agonists. Both κ opioid receptors (KOP-R) (Arvidsson et al. 1995; Mansour et al. 1996; and µ opioid receptors (MOP-R) (Garzon and Pickel 2001; Svingos et al. 2001) are present in significant density in the VTA. Further, microinjections of both KOP-R and MOP-R agonists directly into the VTA produce robust behavioral responses.
The KOP-R agonist U50488H produces conditioned place aversion (Bals-Kubik et al. 1993) . (Charara et al. 1996; Christie et al. 1985; Groenewegen and Berendse 1990; Sesack and Pickel 1992) . There is also indirect evidence that lateral hypothalamic projections to the VTA contain glutamate (Chou et al. 2001; Rosin et al. 2003) . Under physiological conditions, glutamate can induce phasic firing in dopaminergic neurons through the activation of N-methyl-d-aspartate (NMDA) receptors (Chergui et al. 1993; Johnson et al. 1992; Overton and Clark 1997) , and this effect is facilitated by group 1 metabotropic glutamate receptor activation (Zheng and Johnson 2002) . There is also evidence that glutamate activation of 2-amino-3(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid (AMPA) receptors in the VTA can increase extracellular dopamine (DA) in the nucleus accumbens (NAc) (Karreman et al. 1996; Schilstrom et al. 1998 ).
Essential to determining how KOP and MOP receptor agonists in the VTA produce their behavioral actions is elucidating their synaptic effects at the cellular level in all VTA cell types. VTA neurons are classified as principal, secondary, or tertiary according to their electrophysiological and pharmacological properties (Cameron et al. 1997) . Both principal and tertiary neurons exhibit the hyperpolarization-activated non-specific cation current (I h ) and have relatively long duration action potentials. Secondary cells lack an I h and have shorter duration action potentials. They are directly hyperpolarized by MOP-R agonists and are GABA neurons.
Secondary cell inhibition by MOP-R agonists has been proposed to disinhibit principal neurons through local circuitry (Johnson and North 1992; Margolis et al. 2003) . Tertiary neurons differ from principal cells in that they are directly hyperpolarized by MOP-R agonists and serotonin.
While most principal neurons are dopaminergic (about 80%), less than 40% of tertiary neurons are dopaminergic. KOP-R agonists postsynaptically inhibit a subset of both principal and tertiary neurons, an effect limited to dopaminergic neurons of each class (Margolis et al. 2003) .
Despite the evidence that VTA glutamatergic transmission is critical for reward and motivation, our understanding of presynaptic control of glutamate release by opioids is incomplete. We therefore examined the effects of both KOP and MOP receptor agonists on glutamate release onto each VTA cell type. We directly compared KOP and MOP effects within and across individual neurons and neuron types. Because both KOP and MOP effects were observed, we addressed the issue of whether KOP and MOP receptor agonists act on the same terminals by testing whether the effects of the two agonists occluded.
Methods
Twenty to thirty six day old male Sprague-Dawley rats were anesthetized with isofluorane, and their brains were removed. Horizontal slices (200 µm thick) containing the VTA were prepared using a vibratome (Leica Instruments, Germany). Slices were submerged in aCSF solution containing (in mM) 119 NaCl, 2. 
Results
Whole-cell voltage-clamp recordings were made from neurons in the VTA.
Pharmacologically-isolated (100 µM picrotoxin) excitatory postsynaptic currents (EPSCs)
were electrically evoked and we confirmed that this evoked current was due to AMPA receptor activation by blocking the response with the non-NMDA glutamate receptor antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX; 10 µM, n=3).
To address the question of whether opioids differentially alter glutamatergic transmission onto different cell types in the VTA, we classified neurons by their electrophysiological and pharmacological properties as principal, secondary, or tertiary (Margolis et al. 2003) . In most neurons, the changes in stimulated EPSC amplitude following bath application of both the KOP-R selective agonist U69593 (1 µM) and the MOP-R selective agonist DAMGO (3 µM) were measured ( Fig. 1 ). U69593 produced a modest reduction in EPSC amplitude in principal neurons (14 +/-4%), significantly smaller than the DAMGO effect in the same neurons (42 +/-8%, n=11, ANOVA: P<0.01). In contrast, in secondary cells, EPSCs were inhibited to a similar degree by both U69593 (47 +/-10%) and DAMGO (45 +/-10%, n=10). EPSCs in tertiary neurons were also inhibited by both U69593 (33 +/-6%) and DAMGO (35 +/-6%, n=9). Because inhibition by the KOP-R agonist U69593 persisted for at least 15 minutes after washout commenced (1 µM, n=6, data not shown), we used the KOP-R selective antagonist nor-BNI (100 nM) to reverse the KOP mediated inhibition. Application of nor-BNI prior to U69593 completely blocked the KOP-R agonist effect (2 +/-2%, n=3, 1 cell of each type). Because DAMGO was applied a second time to identify the cell type while recording in current clamp mode, in most experiments no antagonist was used to reverse the prolonged presynaptic MOP-R activation response.
However, in a separate set of cells, the application of the MOP-R selective antagonist D-PheCys-Tyr-D-Tryp-Lys-Thr-Pen-Thr-NH2 (CTAP; 500 nM) reversed the DAMGO (3 µM) effect (n=4, data not shown).
Comparing cell types, the observed U69593 effect was significantly larger in secondary and tertiary neurons than in principal neurons (SNK: principal vs secondary, P<0.05; principal vs tertiary, P<0.05). The DAMGO EPSC inhibition was not significantly different among cell types.
To provide evidence that the observed EPSC inhibitions were presynaptic, we examined changes in the paired pulse ratio (PPR) for each drug. A drug-induced decrease in the probability of release is typically correlated with an increase in the paired pulse ratio (Manabe et al. 1993 ). We found no significant differences between the baseline PPRs of the different cell types (principal: 0.9 +/-0.1, n=12; secondary: 1.2 +/-0.2, n=9; tertiary: 0.93 +/-0.06 Hz, n=8
ANOVA: P>0.05).
Although opioid-induced changes in PPR for both U69593 and DAMGO varied greatly across cells and cell types, enhancement of PPR was observed for both receptor types. Figure   2A shows examples comparing baseline evoked EPSCs to those recorded in the presence of either U69593 or DAMGO, and the timecourses of the EPSC amplitude and PPR. This principal neuron exhibited a significant increase in PPR with both drugs. Overall, VTA neurons showed a significant facilitation of paired pulse ratio in the presence of U69593 (n=29, ANOVA: P<0.05, Fig. 2B ) and DAMGO (n=28, ANOVA: P<0.05, Fig. 2C ). However, when broken down by cell type, the only significant effect observed was that produced by DAMGO in secondary neurons.
Individually, less than one third of all neurons (8/30) showed a significant increase in PPR with U69593 (student's t-test, P<0.05), and these neurons were distributed across all 3 cell types.
A slightly higher proportion of neurons showed a significant increase in PPR with DAMGO (11/29), and these, too, included neurons of each type. There was overall a significant linear correlation between the magnitude of EPSC inhibition and the change in PPR for both U69593 there were no differences in baseline frequencies between cell types (principal: 1.3 +/-0.5 Hz, n=8; secondary: 3.9 +/-1.4 Hz, n=9; tertiary: 2.5 +/-0.5 Hz, n=8, ANOVA: P>0.05). U69593 was found to inhibit sEPSCs, but did not change their amplitude (Fig. 3) . Pooled data show that the frequency of sEPSCs significantly decreased from baseline across all cell types in response to both U69593 (ANOVA: P<0.005) and DAMGO (P<0.005, Fig. 3D ). These inhibitions were not accompanied by changes in sEPSC amplitude for either drug (ANOVA: U69593 P>0.05, DAMGO P>0.05, Fig. 3E ). The presence of a decrease in sEPSC frequency and a lack of an effect on sEPSC amplitude are consistent with an opioid induced decrease in glutamate release probability. Further, changes in sEPSC frequency were correlated with U69593-induced decreases in evoked EPSC amplitudes in each cell type (Fig. 3F) . Although only principal neurons showed a significant correlation between evoked EPSC inhibition and sEPSC frequency in the presence of DAMGO, a trend towards a relationship is evident in secondary and tertiary neurons (Fig. 3G) .
In order to ensure that the observed effects on sESPC frequencies were not due to postsynaptic inhibitions of KOP-or MOP-sensitive spontaneously active glutamatergic neurons in the slice that synapse onto the neurons recorded in the preceding experiments, in separate experiments we measured changes in miniature EPSCs (mEPSCs) in the presence of TTX (500 nM). The application of TTX did not change the frequency of observed spontaneous events in any cell type (principal: 1.8 +/-0.6 Hz baseline, 1.6 +/-0.6 Hz TTX, n=7; secondary: 1.6 +/-0.4
Hz baseline, 1.5 +/-0.5 Hz TTX, n=10; tertiary: 1.7 +/-0.3 Hz baseline, 1.4 +/-0.3 Hz TTX, n=8, ANOVA: P>0.05) or amplitude (principal: 14 +/-5 pA baseline, 13 +/-5 pA TTX, n=7; secondary: 13 +/-1 pA baseline, 14 +/-1 pA TTX, n=10; tertiary: 14 +/-2 pA baseline, 12.8 +/-0.6 pA TTX, n=8, ANOVA: P>0.05). The lack of an effect of TTX on either the frequency or the amplitude of spontaneous excitatory events in these neurons suggests that the previously observed sEPSCs are not action potential dependent.
In the presence of TTX, there was a significant inhibition of mEPSC frequency by U69593 (1 µM) among pooled VTA neurons (n=10, ANOVA: P<0.001), with the largest effect occurring in tertiary neurons (Fig. 4A ). There was no change in mEPSC amplitude observed during U69593 application (n=10, ANOVA: P>0.05, Fig. 4B ). In separate experiments, DAMGO (3 µM) also inhibited the frequency of mEPSCs in pooled VTA neurons (n=15, ANOVA: P<0.005, Fig.   4A ). While as a group VTA neurons did show a significant decrease in mEPSC amplitude in the presence of DAMGO (n=15, ANOVA: P<0.05), no individual cell type showed a significant change (Fig. 4B) . That the frequency of mEPSCs decreases with both U69593 and DAMGO further supports a presynaptic mechanism for the observed effects.
A subset of I h -expressing neurons are postsynaptically inhibited by KOP-R agonists (Margolis et al. 2003) . In order to confirm that this postsynaptic effect was not contributing to our evoked presynaptic observations, we compared the evoked presynaptic effects of U69593
in I h expressing (principal and tertiary) neurons in which the KOP-R agonist induced a positive change in the holding current (n=6) to those recorded in neurons that exhibited no change in holding current with U69593 (n=13, Fig. 5A ). There was no difference between the KOP-R agonist-mediated presynaptic inhibitions of EPSCs for these two groups (ANOVA: P>0.05).
Interestingly, there was a significant difference in the MOP-R agonist DAMGO inhibition of evoked EPSCs in these two groups: I h neurons that were postsynaptically hyperpolarized by the KOP-R agonist showed a significantly greater EPSC inhibition during a separate application of DAMGO (ANOVA: P<0.01). Conversely, I h neurons that were postsynaptically inhibited by the MOP-R agonist DAMGO (i.e. tertiary neurons, n=9) sh owed a greater EPSC inhibition by U69593 than those that were not (i.e. principal neurons, n=12, ANOVA: P<0.05, Fig. 5B ). There was no difference in the presynaptic DAMGO effect for neurons postsynaptically inhibited by MOP-R agonists compared to those that were not (Fig. 5B ).
For both MOP and KOP receptor agonists, the largest presynaptic EPSC inhibitions were observed in secondary neurons, and only secondary cells showed a significant correlation between KOP and MOP receptor agonist EPSC inhibitions (Fig. 6 ). It is interesting to note that the EPSCs in a subset of secondary neurons (3/9) were inhibited more than 75% by both U69593
and DAMGO, a much larger effect than that observed in any principal or tertiary neuron. In the example traces in Fig. 1 , the evoked EPSC signal appeared completely blocked, and this was typical of all 3 secondary neurons with these large evoked EPSC inhibitions. This effect would require that KOP and MOP receptors colocalize on glutamatergic terminals synapsing on to at least a subpopulation of secondary neurons.
To address the question of whether MOP-Rs and KOP-Rs are segregated or are colocalized on the same glutamate terminals synapsing onto I h expressing neurons we carried out occlusion experiments in principal and tertiary neurons. After a stable baseline was obtained, DAMGO was added to the bath and the EPSC inhibition was allowed to stabilize. The addition of U69593 resulted in an additional inhibition of EPSC amplitude in all I h neurons (n=8, Fig. 7A ). Further, while there was no difference between the magnitude of the U69593 effect in the presence (8 +/-3%, n=4) or absence of DAMGO among principal neurons, the U69593-mediated EPSC inhibition in tertiary neurons was significantly smaller in the presence of DAMGO (10 +/-3%, n=4) than in aCSF alone (ANOVA: P<0.05, Fig. 7B ). These data are consistent with the hypothesis that MOP-Rs and KOP-Rs segregate to separate glutamatergic inputs to principal neurons, but require that at least some MOP-Rs and KOP-Rs are colocalized on glutamatergic terminals that synapse onto tertiary neurons. reported for the 7 neurons tested with U69593 in that study, an EPSC inhibition is likely to have occurred in a subset of those neurons. The variability of KOP inhibition across all I h neurons reported here may have led to an average effect that was not significantly different from zero in their study when principal and tertiary neurons were not distinguished. The small but significant U69593 effect we observed in principal neurons was not only confirmed by sEPSC and mEPSC measurements, but was reversed by nor-BNI, confirming its KOP-R selectivity.
Discussion
We observed a previously unreported and significant relationship between the pre-and postsynaptic effects of KOP and MOP receptor agonists in I h neurons. The EPSC inhibition by KOP-R agonists was larger among neurons postsynaptically hyperpolarized by MOP-R agonists (i.e., tertiary neurons), and MOP-mediated EPSC inhibition was larger in neurons postsynaptically inhibited by KOP-R agonists. Interestingly, while about 70% of I h expressing neurons in the VTA are dopaminergic, all neurons hyperpolarized by KOP are dopaminergic (Margolis et al. 2003) . Although there are also DA neurons that are not inhibited by KOP-R agonists, the data reported here suggest that glutamatergic inputs to DA neurons are more sensitive to MOP-R agonists than those onto non-DA, I h expressing neurons. This conclusion will need to be confirmed in future experiments.
The inhibition of excitatory input to DA neurons by MOP-R agonists seems counter to the observation that MOP-R agonists in the VTA excite DA neurons. However, it is possible that the function of MOP-R activation in the VTA is to increase firing rate without producing bursting in DA neurons. Glutamate input to DA neurons tends to shift the tonic, spontaneous activity of DA neurons to a bursting pattern, often without changing the overall firing rate of the neuron The sources of the differences in the responses to opioids reported here and their possible functional implications are unclear. Since in most cases, especially in the principal neurons, inhibition of glutamatergic inputs by KOP-R ligands was only partial, it is likely that not all glutamatergic terminals bear the KOP-R. Thus, it is tempting to hypothesize that variation in EPSC modulation by opioids across cell types depends on the source of glutamatergic afferents.
For instance, Carr and Sesack (2000) demonstrated that glutamate afferents from the mPFC to the VTA synapse selectively on DA neurons that project back to the mPFC and GABAergic neurons that project to the NAc, but not DA neurons that project to the NAc or GABA neurons that project to the mPFC. Therefore, some combination of PPN, STN, and hypothalamus afferents to the VTA likely provides major glutamate input to the non-dopaminergic neurons that comprise 60% of the VTA projection to the mPFC, the dopaminergic neurons that comprise 80% of the VTA projection to the NAc, and possibly the VTA neurons that project to other targets such as the amygdala and hippocampus (Swanson 1982) . However, since in other brain regions a single axon can give rise to multiple excitatory synapses with significantly different properties (Maccaferri et al. 1998; Markram et al. 1998; Scanziani et al. 1998) , we cannot conclude that the observed differences are due to differential anatomical origins of the glutamatergic afferents.
Further work needs to be done to discern if there is indeed an anatomical correlate to the effects observed here.
In conclusion, we demonstrate that KOP and MOP receptor agonists inhibit glutamatergic input onto all neuron types in the VTA. Presynaptic regulation of synaptic transmission by opioids in the VTA provides a mechanism for selective control of specific inputs to VTA neurons.
How these presynaptic effects interact with the postsynaptic inhibitions through MOP and KOP receptor activation in the VTA not only depends on whether the glutamatergic afferents are active when opioid ligands are present, but may also depend on the site of origin of the neuron giving rise to the glutamatergic terminal, or the projection target of the postsynaptic neuron.
The modulation of glutamate release by KOP and MOP receptor agonists reported here provides important information for understanding signal modulation in the VTA, and is an important key to elucidating the influence on motivation and reward of endogenous opioids acting in the VTA. A, This example neuron shows a significant paired pulse facilitation in response to both U69593
(1 µM) and DAMGO (3 µM). 
